Gregory E Harris1, Lise Dupuis2, Gerald J Mugford3, Lynn Johnston4, David Haase5, Ginny Page6, Heather Haldane7, Nicholas Harris8, William K Midodzi9, Gordon Dow10. 1. Faculty of Education, Memorial University of Newfoundland, St John's, Newfoundland and Labrador; 2. Horizon Health Network, Moncton, New Brunswick; 3. The Health Sciences Centre, Faculty of Medicine (Medicine and Psychiatry), St John's, Newfoundland and Labrador; 4. Department of Medicine, Faculty of Medicine, Capital District Health Authority; 5. Capital District Health Authority and Dalhousie University; 6. QEII Health Sciences Centre, Victoria General Hospital Site; 7. Department of Infectious Diseases, Center for Clinical Research, Halifax, Nova Scotia; 8. Lakehead University, Thunder Bay, Ontario; 9. Faculty of Medicine, Memorial University, St John's, Newfoundland and Labrador; 10. Dalhousie University, The Moncton Hospital, Moncton, New Brunswick.
Abstract
BACKGROUND: The prevalence of cannabis use in HIV-infected individuals is high and its long-term effects are unclear. METHODS: The prevalence, perceived benefits and consequences, and predictors of cannabis use were studied using a cross-sectional survey in two immunodeficiency clinics in Maritime Canada. RESULTS: Current cannabis use was identified in 38.5% (87 of 226) of participants. Almost all cannabis users (85 of 87 [97.7%]) acknowledged its use for recreational purposes, with 21.8% (19 of 87) reporting medicinal cannabis use. The majority of patients enrolled in the present study reported mild or no symptoms related to HIV (n=179). Overall, 80.5% (70 of 87) of the cannabis-using participants reported a symptom-relieving benefit, mostly for relief of stress, anorexia or pain. Participants consumed a mean (± SD) of 18.3±21.1 g of cannabis per month and spent an average of $105.15±109.87 on cannabis per month. Cannabis use was associated with rural residence, lower income level, driving under the influence of a substance, and consumption of ecstasy and tobacco. Income level, ecstasy use and tobacco use were retained as significant predictors in regression modelling. Cannabis use was not associated with adverse psychological outcomes. DISCUSSION: Prolonged previous cannabis consumption and the substantial overlap between recreational and medicinal cannabis use highlight the challenges in obtaining a tenable definition of medicinal cannabis therapy.
BACKGROUND: The prevalence of cannabis use in HIV-infected individuals is high and its long-term effects are unclear. METHODS: The prevalence, perceived benefits and consequences, and predictors of cannabis use were studied using a cross-sectional survey in two immunodeficiency clinics in Maritime Canada. RESULTS: Current cannabis use was identified in 38.5% (87 of 226) of participants. Almost all cannabis users (85 of 87 [97.7%]) acknowledged its use for recreational purposes, with 21.8% (19 of 87) reporting medicinal cannabis use. The majority of patients enrolled in the present study reported mild or no symptoms related to HIV (n=179). Overall, 80.5% (70 of 87) of the cannabis-using participants reported a symptom-relieving benefit, mostly for relief of stress, anorexia or pain. Participants consumed a mean (± SD) of 18.3±21.1 g of cannabis per month and spent an average of $105.15±109.87 on cannabis per month. Cannabis use was associated with rural residence, lower income level, driving under the influence of a substance, and consumption of ecstasy and tobacco. Income level, ecstasy use and tobacco use were retained as significant predictors in regression modelling. Cannabis use was not associated with adverse psychological outcomes. DISCUSSION: Prolonged previous cannabis consumption and the substantial overlap between recreational and medicinal cannabis use highlight the challenges in obtaining a tenable definition of medicinal cannabis therapy.
Authors: J E Beal; R Olson; L Laubenstein; J O Morales; P Bellman; B Yangco; L Lefkowitz; T F Plasse; K V Shepard Journal: J Pain Symptom Manage Date: 1995-02 Impact factor: 3.612
Authors: Chukwuemeka N Okafor; Zhi Zhou; Larry E Burrell; Natalie E Kelso; Nicole E Whitehead; Jeffery S Harman; Christa L Cook; Robert L Cook Journal: Am J Drug Alcohol Abuse Date: 2016-07-11 Impact factor: 3.829
Authors: Albert Y Liu; Aliza Norwood; Holly Gundacker; Alex Carballo-Diéguez; Sherri Johnson; Karen Patterson; Linda-Gail Bekker; Suwat Chariyalertsak; Anupong Chitwarakorn; Pedro Gonzales; Timothy H Holtz; Kenneth H Mayer; Carmen Zorrilla; Susan Buchbinder; Jeanna M Piper; Javier R Lama; Ross D Cranston Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Chukwuemeka N Okafor; Robert L Cook; Xinguang Chen; Pamela J Surkan; James T Becker; Steve Shoptaw; Eileen Martin; Michael W Plankey Journal: AIDS Behav Date: 2017-04
Authors: Cecilia T Costiniuk; Zahra Saneei; Syim Salahuddin; Joseph Cox; Jean-Pierre Routy; Sergio Rueda; Sara J Abdallah; Dennis Jensen; Bertrand Lebouché; Marie-Josée Brouillette; Marina Klein; Jason Szabo; Charles Frenette; Andreas Giannakis; Mohammad-Ali Jenabian Journal: Cannabis Cannabinoid Res Date: 2019-09-23
Authors: Ada R Miltz; Alison J Rodger; Janey Sewell; Richard Gilson; Sris Allan; Christopher Scott; Tariq Sadiq; Paymaneh Farazmand; Jeffrey McDonnell; Andrew Speakman; Lorraine Sherr; Andrew N Phillips; Anne M Johnson; Simon Collins; Fiona C Lampe Journal: Int J Drug Policy Date: 2021-01-23
Authors: Patricia E Molina; Angela M Amedee; Peter Winsauer; Steve Nelson; Gregory Bagby; Liz Simon Journal: J Neuroimmune Pharmacol Date: 2015-03-21 Impact factor: 4.147
Authors: Douglas Bruce; Alida M Bouris; Shannon Bowers; Olivia Blocker; Soo Young Lee; Mary F Glidden; John A Schneider; Daniel H Reirden Journal: Addict Res Theory Date: 2019-06-26
Authors: Joëlla W Adams; Kendall J Bryant; E Jennifer Edelman; David A Fiellin; Julie R Gaither; Adam J Gordon; Kirsha S Gordon; Kevin L Kraemer; Matthew J Mimiaga; Don Operario; Janet P Tate; Jacob J van den Berg; Amy C Justice; Brandon D L Marshall Journal: AIDS Behav Date: 2018-04
Authors: Frank Y Chou; Heather L Armstrong; Lu Wang; Nicanor Bacani; Nathan J Lachowsky; Thomas L Patterson; Zach Walsh; Gbolahan Olarewaju; Kiffer G Card; Eric A Roth; Robert S Hogg; David M Moore Journal: J Affect Disord Date: 2019-01-15 Impact factor: 4.839